Tarcocimab Biosimilar Monoclonal Antibody (VEGF-A) for Research

Cat No.: GMP-Bios-INN-1009

Anti-VEGFA therapeutic antibody (Pre-made Tarcocimab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1009-1mg 1mg 3090
GMP-Bios-INN-1009-10mg 10mg
GMP-Bios-INN-1009-100mg 100mg
GMP-Bios-INN-1009-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Tarcocimab Biosimilar, Whole Mab, Anti-Vegfa Antibody: Anti-MVCD1/VEGF/VPF therapeutic antibody
INN Name Tarcocimab
TargetVEGFA
FormatWhole mAb
DerivationHumanized
Species Reactivityhuman
CH1 IsotypeIgG1 - kappa
VD LCIgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesKodiak Sciences, USA (Palo Alto CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0



About target - VEGFA

1. Protein Vascular endothelial growth factor A

2. Gene VEGFA

3. Organism Homo sapiens (Human)

Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity).